October 25, 2016—Socially responsible investors want 17 leading U.S. and foreign drug companies to provide “more comprehensive disclosure about the rationale for price increases.”
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)